The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,913 GBX | +3.18% | +6.34% | +6.93% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+6.93% | 5.14B | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |